When the US Food and Drug Administration scheduled a June in-person meeting of its ophthalmic devices panel it seemed to indicate that the agency was hoping to get back to some form of normalcy by then. However, due to the ongoing coronavirus crisis it has now postponed the meeting until further notice.
On 1 April the FDA’s Center for Devices and Radiological Health announced it was planning on assembling a panel of experts on 9 June to discuss a new implant to treat the natural aging of the eye. The agency had already either cancelled or postponed other meetings up to that point, and the announcement was seen as a sign that the federal government was anticipating getting back to normal business by then
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?